Abstract

The present invention solves the problem of providing novel and improved therapeutic compounds for preventing and/or treating cancer, such as ovarian cancer. The present invention provides compounds targeting TPM1 alternative splicing variants Tpm1.8 and/or Tpm1.9. The compounds or a pharmaceutical composition comprising at least one compound according to the present invention counteracts chemoresistance, such as chemoresistance to taxane- and/or platinum-based chemotherapeutic agents. Further, the present inventions includes a method for identifying compounds targeting Tpm1.8 and/or Tpm1.9 isoforms which have a therapeutic effect in inhibiting, suppressing, preventing and/or treating cancer.

IPC Classes  ?

• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/04 - Antineoplastic agents specific for metastasis

Abstract

The present invention solves the problem of providing novel and improved therapeutic agents for preventing and/or treating Hepatitis E virus (HEV) infections. The present invention provides guanosine nucleotide analogs or a pharmaceutical composition comprising said analogs for preventing and/or treating HEV infections. The guanosine nucleotide analogs or a pharmaceutical composition comprising guanosine nucleotide analogs for preventing and/or treating HEV infections are for example administered in combination with one or more additional antivirals, such as IFN-α and/or ribavirin. Further, the present invention also provides a method of preventing and/or treating a HEV infection in a subject, comprising the step of administering a therapeutically effective amount of the guanosine nucleotide analogs to said subject.

IPC Classes  ?

• A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
• A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention provides a method for determining whether a sample comprises inducible HIV-1, the method comprising performing a reverse transcription, loop-mediated isothermal amplification (RT-LAMP) reaction with said sample with a primer set specific for Tat/Rev multiply spliced (ms) HIV-1 RNA and determining whether the sample comprises an amplification product of the RT-LAMP reaction, wherein the binding sites for the F2 and F1 primer or for the B2c and B1c primer of said primer set span a region in said Tat/Rev ms HIV-1 RNA that overlaps with the splice site of the intron interrupting the Tat and Rev coding sequences.

IPC Classes  ?

• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage

Abstract

The present invention relates to an alpha spectrometry scanner for measuring one or more characteristics of radiation particles received from a radioactive sample under test, which sample is comprised in a radiopharmaceutical, said scanner comprising: detector means comprising a pixelated detector comprising a two dimensional array of detector pixels sensitive to said radiation particles received from said sample; a readout circuit in electric communication with said detector means, arranged to readout each pixel of said array, and wherein said readout circuit is arranged to generate, based on said readout of each of said detector pixels, a charge pattern for each hit of a radiation particle on said detector means, said charge pattern comprising spatial data, temporal data and energy deposited for each detector pixel of said array; spectroscopic analyser means in electric communication with said readout circuit to receive each charge pattern generated by said readout circuit, wherein said spectroscopic analyser means are arranged with a selective algorithm to extract features from said charge pattern and to identify and quantify a corresponding alpha particle of said sample based on said extracted features; a collimator arranged for selecting radiation particles that are on a path from said radioactive sample under test, towards said detector means, wherein said collimator is positioned in front of said detector means, and is comprised of an alpha particle vacuum collimator or an alpha particle air-flush collimator, said vacuum collimator or air-flush collimator is arranged to restrict the passage of said radiation particles and select particles on the path towards the pixels of the array of the pixelated detector.

IPC Classes  ?

• G01T 1/29 - Measurement performed on radiation beams, e.g. position or section of the beamMeasurement of spatial distribution of radiation
• G01T 1/24 - Measuring radiation intensity with semiconductor detectors
• G01T 1/36 - Measuring spectral distribution of X-rays or of nuclear radiation

Abstract

The invention relates to the field of flow cytometry and more particularly to a panel of antibody reagents conjugated to fluorescent compounds. Provided are reagent compositions, comprising at least eight distinct fluorochrome-conjugated antibodies comprising a set of at least three identification antibodies for the identification of a leukocyte population of interest and at least four characterization antibodies for further characterization and/or classification of said leukocyte population. Also provided are kits and methods related to the reagent compositions.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
• G01N 15/1404 - Handling flow, e.g. hydrodynamic focusing
• G01N 33/49 - Physical analysis of biological material of liquid biological material blood
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/532 - Production of labelled immunochemicals
• G01N 33/533 - Production of labelled immunochemicals with fluorescent label

Abstract

An aspect of the disclosure relates to an ultrasound imaging system comprising: an ultrasound imaging device comprising an ultrasound transducer configured to transmit and receive ultrasound signals; and an ultrasound receiver device that is separable from the ultrasound imaging device, the ultrasound receiver device comprising: one or more ultrasound receiver elements configured to receive ultrasound signals, in which the one or more ultrasound receiver elements and the one or more ultrasound transducers are configured to operate simultaneously; an external housing configured to separate the one or more ultrasound receiver elements from the ultrasound imaging device, in which the one or more ultrasound receiver elements are within the external housing.

IPC Classes  ?

• G01S 7/52 - Details of systems according to groups , , of systems according to group
• G01S 15/89 - Sonar systems specially adapted for specific applications for mapping or imaging
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves

Abstract

This invention relates to the field of primary immunodeficiencies (PID), more specifically to means and method for the diagnosis of PID of the lymphoid system. Provided are unique reagent compositions for the flow cytometric immunophenotyping of leukocytes comprising fluorochrome-conjugated antibodies directed against various specific combinations of markers. Also provided are kits comprising the reagent compositions, and methods using the same.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 15/01 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
• G01N 15/10 - Investigating individual particles
• G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
• G01N 33/49 - Physical analysis of biological material of liquid biological material blood

Abstract

The present invention refers to a marker set for determining a PCL-like transcriptomic status in a sample which is indicative for a disease. Further, a method for determining a PCL-like transcriptomic status in a sample is provided by the present invention. In addition, the marker set and/or the method of the present invention is used for selecting an active agent for use in the treatment and/or prevention of a disease. In addition, the present invention refers to kits comprising means for determining the PCL-like transcriptomic status based on the marker set in a sample.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Methods are provided for treating an individual with cytotoxic T lymphocyte exhaustion by administering an effective dose of an annexin V agent. In some embodiments, the individual undergoing treatment is infected with HIV. The individual may be treated with highly active antiretroviral therapy (HAART).

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans

Abstract

A transgenic non-human mammal containing a heterologous lambda light chain gene locus, and/or a heterologous kappa light chain gene locus, and/or a heterologous heavy chain gene locus, each of which can re-arrange so that immunoglobulin heavy and light chain genes are formed and expressed in B-cells following antigen challenge.

IPC Classes  ?

• A01K 67/0278 - Knock-in vertebrates, e.g. humanised vertebrates
• A01K 67/0276 - Knock-out vertebrates
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12P 21/00 - Preparation of peptides or proteins

Abstract

According to one aspect, an interstitial hyperthermia device has an electrode structure to be coupled to an electric power source for providing an alternating electric field for heating up a patients tissue. The device is provided with a hollow source guide for conducting a radiation source capsule to be moved by a guidewire. The hollow source guide has an inner wall for guiding the source capsule and an outer wall to be contacted with the patients tissue. The outer wall is provided with the electrode structure arranged on a circumference of the outer wall of the hollow source guide and having a dielectric layer shielding the electrode structure from the patients tissue.

IPC Classes  ?

• A61N 1/40 - Applying electric fields by inductive or capacitive coupling
• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy

Abstract

Described herein is a composition and method of preventing COVID-19 with lipid-peptide fusion antiviral therapy.

IPC Classes  ?

• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 31/14 - Antivirals for RNA viruses
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses

Abstract

The invention relates to a group of Y-chromosomal short tandem repeat (Y-STR) markers comprising at least one rapidly mutating (RM) Y-STR marker selected from the group consisting of DYF1000, DYF1001, DYF1002, DYR88, DYS685, DYS688, DYS712, DYS1003, DYS1007, DYS1010 and DYS1012. The invention further relates to a set of amplification primers comprising primers for the amplification of at least one Y-STR marker according to the invention, to methods for amplifying an allele of at least one Y-STR marker, to a kit for identifying an allele of a Y-STR marker by amplification and electrophoretic detection or sequencing detection, and by sequencing of non-amplified DNA, and to the use of the group of Y-STR markers for typing male individuals.

IPC Classes  ?

• C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms

Abstract

Provided herein are bispecific antibodies comprising a first antigen binding region and a second antigen binding region, wherein the first antigen binding region binds to CD117 and comprises a first heavy chain variable region and a first light chain variable region, and the second binding reigon binds to CD3 and comprises a second heavy chain variable region and a second light chain variable region. Also provided are compositions comprising the bispecific antibodies as well as uses of the bispecific antibodies and compositions.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• C07K 16/46 - Hybrid immunoglobulins
• A61P 35/00 - Antineoplastic agents
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

The present invention provides a pharmaceutical combination for use in treating cancer comprising an ITK inhibitor and an immune checkpoint inhibitor, wherein the ITK inhibitor is formulated for intermittent administration or for administration at a dose that partially inhibits ITK enzymatic activity in T cells. The present invention further provides a method of reversing T cell exhaustion resulting from persistent TCR stimulation comprising exposing an exhausted T cell to an ITK inhibitor, wherein said T cell may be a CD8+ T cell or a CAR T cell.

IPC Classes  ?

• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present invention provides an in vitro method for determining the physiological age of blood platelets in a test sample wherein said physiological age is expressed in days and/or hours. The method comprises providing a test sample of blood platelets, determining the level of expression of one or more of tubulin, VWF, SPARC, CD63 and PF4 in one or more of individual platelets within said test sample, and determining, based on the level of expression determined, the physiological age of the blood platelets in said test sample. Preferably, the method comprises the using a machine learning data processing model.

IPC Classes  ?

• C12Q 1/56 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
• G01N 33/86 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood coagulating time

Abstract

The invention relates to nucleic acid molecules comprising a nucleotide sequence encoding a metabolic protein or a part thereof or a sequence having at least 90% sequence identity to said metabolic protein or part thereof, a human insulin-like growth factor II (IGFII) gene sequence, and a nucleotide sequence encoding at least one peptide that facilitates cellular uptake or transcytosis which is inserted at a location between the nucleotides encoding amino acids 28 and 42 of mature IGFII of said IGFII gene sequence. The invention further relates to related viral particles, fusion proteins and uses thereof.

IPC Classes  ?

• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/86 - Viral vectors
• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)

Abstract

The invention provides inter alia an engineered T cell, wherein said T cell is engineered to express a T cell receptor (TCR) or an antibody-based receptor that binds to a T cell epitope of human ropporin-1A (ROPN1) or human ropporin-1B (ROPN1B); wherein said T cell epitope is selected from the group consisting of SEQ ID NO:4, SEQ ID NO:43, SEQ ID NO:23, SEQ ID NO:56 and SEQ ID NO:24.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 14/725 - T-cell receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present invention is directed to a scaffold and a compound for targeting fibroblast activation protein (FAP) in cancer-associated fibroblasts (CAFs). The scaffold comprises a (4-quinoinolyl)glycinyl-2-cyanopyrrolidine scaffold that is substituted on the 8th22 or O; R132523232223222222m22m22, wherein m is 1-4; and R2and R3 each independently represent H or F.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 411/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 498/18 - Bridged systems
• A61P 35/00 - Antineoplastic agents
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings

Abstract

A catheter-based imaging apparatus comprises a catheter having a proximal end and a distal end. An optical emitter is configured to emit optical excitation signals from a distal portion of the catheter. One or more ultrasound transducers are configured for: (a) transmission of acoustic excitation signals from the distal portion of the catheter; and (b) detection of ultrasound response signals from an object of interest at or near to the distal portion of the catheter at frequencies which include a lower receive frequency at least as low as 10 MHz and a higher receive frequency at least as high as 35 MHz. The one or more ultrasound transducers are thereby configured to detect response signals comprising photoacoustic response signals from the object of interest at the lower receive frequency and high resolution imaging signals from the object of interest at the higher receive frequency.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/02 - Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
• A61B 8/08 - Clinical applications
• A61B 8/12 - Diagnosis using ultrasonic, sonic or infrasonic waves in body cavities or body tracts, e.g. by using catheters
• B06B 1/06 - Processes or apparatus for generating mechanical vibrations of infrasonic, sonic or ultrasonic frequency making use of electrical energy operating with piezoelectric effect or with electrostriction
• G01S 15/89 - Sonar systems specially adapted for specific applications for mapping or imaging

Abstract

The invention relates to antibody conjugates comprising an antibody and a nanoparticle conjugated to the antibody, wherein the nanoparticle comprises a payload, such as a gene editing payload. In some embodiments, the antibody-conjugated nanoparticles provide a means for treating a disease. In some embodiments, the antibody-conjugated nanoparticles are used to correct genetic defects in specific cell populations.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• C12N 9/22 - Ribonucleases
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid

Abstract

The invention is directed to a pharmaceutical compound, or a pharmaceutically acceptable salt thereof, for use in a medical treatment or diagnosis of tumors, in particular neuroendocrine tumors (NET). The compound is according to the formula Ch(M)–L–T, wherein Ch represents a radioisotope chelator; M represents the radioisotope; T represents a sstr2-agonist; L represents a linker comprising a moiety having a six-membered cyclic structure.

IPC Classes  ?

• A61K 51/08 - Peptides, e.g. proteins
• A61K 103/00 - Radioactive metals
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings

Abstract

The present invention provides an anti-cancer vaccine composition comprising a cancer neoantigen comprising a CTL epitope, the composition further comprising as adjuvants a combination of a CpG ohgonucleotide and a STING agonist.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention provides an antiviral vaccine composition, comprising a viral coat, matrix or core/capsid (glyco)protein as antigen, and an adjuvant combination of a CpG oligonucleotide and a STING agonist.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to nucleic acid molecules comprising a nucleotide sequence encoding an amino acid sequence having at least 90% sequence identity with amino acids 28-952 of human acid alpha glucosidase (GAA) and a human insulin-like growth factor II (IGFII) gene sequence located 5' of the nucleotide sequence encoding an amino acid sequence having at least 90% sequence identity with amino acids 28-952 of human GAA, to encoded fusion proteins, and uses thereof.

IPC Classes  ?

• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/867 - Retroviral vectors

Abstract

A system (100) and method for measuring tissue (T). A chamber (20) is configured to hold a liquid medium (L). Two attachments structures with respective tissue engaging sections (12) are configured to hold the tissue (T) there between inside the chamber (20c) and submerged in the liquid medium (L). At least one of the attachments structures is formed by a cantilever (10). The cantilever (10) comprises a respective bending section (11) formed by an elongate strip with a flat surface (11f) fixated at one end of the cantilever (10) and configured to bend with an, opposite, free end of the cantilever (10) in a direction normal to the flat surface (11f). The respective tissue engaging section (12) is connected at the free end of the cantilever (10) to the respective bending section (11) and configured to hold a respective part of the tissue (T) at said free end.

IPC Classes  ?

• C12M 1/42 - Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic wave
• C12M 1/36 - Apparatus for enzymology or microbiology including condition or time responsive control, e.g. automatically controlled fermentors
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

A stent delivery system (100) comprises a balloon-inflatable stent (10) with a guide wire (31) for guiding the stent (10) into a target vessel (V1) for treating a stenosis (4) in the target vessel (V1) with the stent (10) to be delivered at a predetermined stent position (Xs). An anchor wire (32) is provided through an anchor port (52) for anchoring the stent (10) by entering into a lumen or second vessel (V2) branching from the target vessel (V1) at a branching position (Xb). The anchor port (42) is freely adjustable along a length (ΔX) of the guide wire (31) for adjusting the anchor position (Xa) relative to the stent position (Xs), or vice versa. An anchor positioning means (41) is connected to the anchor port (42) and configured to control said freely adjustable anchor position (Xa) relative to the stent position (Xs), e.g. by pushing and pulling on a hypotube.

IPC Classes  ?

• A61F 2/958 - Inflatable balloons for placing stents or stent-grafts
• A61M 25/00 - CathetersHollow probes
• A61F 2/954 - Instruments specially adapted for placement or removal of stents or stent-grafts for placing stents or stent-grafts in a bifurcation

Abstract

The current invention pertains an inhibitor of an S100 protein, preferably an inhibitor of an S100A8 or S100A9 protein, for the prevention or treatment of a myeloproliferative neoplasm. In particular, the invention pertains to an inhibitor of an S100A8 or S100A9 protein, for the prevention or treatment of primary myelofibrosis. The invention further pertains to an diagnostic method for identifying a subject suffering from a myeloproliferative neoplasm, comprising a step of detecting the presence of an S100 protein, preferably S100A8 or S100A9, in a biological sample.

IPC Classes  ?

• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The invention provides a follistatin in combination with a bisphosphonate for use in a method of counteracting a condition of bone loss and/or muscle loss in a subject.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 31/663 - Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• A61P 21/06 - Anabolic agents

Abstract

The present invention provides a method of spreading DNA fibers on a surface of a microscope slide for microscopic analysis, the method comprising the steps of (i) providing a cell or cellular compartment comprising DNA fibers to be analyzed; (ii) providing a microscope slide for microscopic analysis; (iii) providing a container holding an amount of a liquid lysis composition for lysing said cell or cellular compartment; (iv) adhering said cell or cellular compartment to the surface of said microscope slide; (v) transferring said slide with said cell or cellular compartment adhered thereto to said container thereby substantially submerging said slide in said lysis composition, wherein said slide is placed in said lysis composition at a predetermined angle with respect to the horizontal plane of between 45° and 90°, and wherein the adhered cell or cellular compartment is facing upward; and (vi) allowing lysis of said cell or cellular compartment adhered to said slide, and removing said lysis composition from said container at a controlled and constant rate of flow by use of a liquid pump to thereby facilitate spreading of the DNA fibers on the surface of said microscope slide.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

Abstract

The invention relates to a device (1) and a method for obtaining an indicator of the microcirculatory condition of a patient. the device (1) comprises at least one sensor (2) for measuring data indicative of an arterial blood oxygen level, at least one sensor (3) for measuring data indicative of a tissue oxygen level and a control unit (4) for determining a measure of microcirculation, in particular changes in tissue perfusion on the basis of the tissue oxygen level and the arterial blood oxygen level.

IPC Classes  ?

• A61B 5/026 - Measuring blood flow
• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
• A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition

Abstract

The invention relates to a device (1, 1′) and a method for obtaining an indicator of microcirculatory condition of a patient. The device (1, 1′) comprises at least one first sensor (13) for measuring data indicative of first carbon dioxide levels, in particular tissue carbon dioxide levels, at least one second sensor (12) for measuring data indicative of second carbon dioxide levels, in particular transcutaneously measured arterial blood carbon dioxide levels, and a control unit (4) for determining a measure of microcirculation, in particular changes in tissue perfusion, preferably in septic patients, on the basis of the tissue carbon dioxide level and the transcutaneously measured arterial blood carbon dioxide level.

IPC Classes  ?

• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
• A61B 5/1477 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means non-invasive
• A61B 5/1491 - Heated applicators
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

in vitroin vitroin vitro condition wherein said oligomerization-modulating compound is absent, wherein said oligomerization-modulating compound is selected from a protein interacting with said oligomeric protein or its protein subunits, a nucleoside phosphate or an hydrolysis-resistant analogue thereof, or a (de)stabilizing small molecule; b) arresting the oligomerization of said protein oligomer by addition of a cross-linking agent to thereby provide said protein oligomer in a stabilized quaternary conformation and specific oligomeric state; c) using the protein oligomer in said stabilized quaternary conformation and specific oligomeric state of step (b) as a conformation-specific antigen of said protein oligomer to immunize a non-human mammal, optionally in combination with an adjuvant, to thereby obtain antibodies against said conformation-specific antigen; d) selecting an antibody obtained in step (c) that binds to the said conformation-specific antigen but not to said protein subunits, to thereby obtain a conformation-specific antibody against said oligomeric protein in a specific oligomeric state.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

The invention provides novel immunogenic peptides derived from the X protein and polymerase protein of hepatitis B virus (HBV). The peptides contain epitopes that are well-conserved across multiple HBV variants and are derived from regions of proteins that are essential for viral replication. Moreover, the novel HBV antigens bind multiple HLA types and epitopes that elicit IFNγ responses in PBMCs from HBV resolvers have been identified.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• A61K 39/29 - Hepatitis virus
• A61P 31/20 - Antivirals for DNA viruses
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention provides a reporter system comprising (i) a gene expression construct for expression in a cell of a reporter gene, said reporter gene encoding a fusion protein comprising a transmembrane domain fused in-frame to a reporter domain, wherein said transmembrane domain upon insertion of the fusion protein into the cell membrane anchors the fusion protein in the cell membrane while expressing the reporter domain at the cell surface, and (ii) a reporter peptide labeled with a radiolabel, wherein said reporter domain comprises the large polypeptide subunit of a split luciferase, and wherein said reporter peptide comprises the small peptide subunit of said split luciferase, wherein both subunits associate by complementation to assemble into a luciferase complex.

IPC Classes  ?

• A61K 51/08 - Peptides, e.g. proteins
• C12Q 1/66 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving luciferase
• C12N 15/86 - Viral vectors

Abstract

The present invention provides a method for the combined taxonomic identification and determination of antimicrobial drug resistance of a microorganism, proteins of which are present in a sample, the method comprising subjecting a sample comprising proteins of a microorganism to an endoprotease to provide a mixture of peptides from said proteins, and analyzing the mixture of peptides by high-resolution mass spectrometry using a single high resolution mass spectrometry technique in two separate data acquisition modes, wherein said modes consist of DDA and PRM, and wherein said two separate data acquisition modes are performed subsequently or in parallel in a single mass spectrometric analysis run.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

A method of manufacturing a microstructure comprises printing a positive mold structure, filling the positive mold structure with a second material to form an elastically deformable negative mold structure, filling the negative mold structure with a third material to form the microstructure, and releasing the microstructure from the negative mold structure. Advantageously, the negative mold structure can be stretched to facilitate the release of the microstructure. For example, the microstructure comprises a chamber with capped micropillars for the generation and/or analysis of muscle tissue.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means

Abstract

The invention provides a BAF complex modulating compound for use as a coronavirus antiviral; wherein the BAF complex modulating compound is of Formula (I):

IPC Classes  ?

• C07D 273/02 - Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups having two nitrogen atoms and only one oxygen atom
• A61K 9/00 - Medicinal preparations characterised by special physical form
• C07D 273/08 - Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups having two nitrogen atoms and more than one oxygen atom
• C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

The disclosure relates to methods and devices for monitoring the concentration of a substance, preferably oxygen, in a cell or tissue, e.g., in cells of the human skin. In particular, it provides a method for determining the concentration of a quencher, such as oxygen and/or the concentration of a probe, e.g., a heme precursor such as protoporphyrin IX (PpIX), wherein the probe is capable of exhibiting luminescence (delayed fluorescence (DF) or phosphorescence) and or transient triplet absorption, preferably, deDF, in a living cell. The method comprises steps of exciting the probe, measuring the lifetime of the luminescence exhibited by said probe, herein, in the presence of the quencher, the lifetime is shortened as compared to the lifetime in the absence of the quencher, and correlating said lifetime with said concentration. The disclosed method leads to more precise results than conventional methods, because of adaptations based on the understanding of the influence of the concentration of the probe and its excitation fluence rate (intensity) on the analysis. For example, the simultaneous time-resolved detection of the probe excimer and monomer DF allows estimation of the probe concentration and compensation of the probe self-quenching effect in the quencher concentration calculation, increasing the measurement precision. Taking into account second order triplet interactions also permits the interpretation of non-exponential decays and further improvement of the quencher and probe concentration estimation. Disclosed methods rely, e.g., on measurement at different emission wavelengths and application of an adaptive Stern-Volmer relationship, the decay central fitting method and/or a mixed orders approach. Said method can be applied, e.g., for bedside monitoring of patients. Also disclosed is the use of the PpIX precursor 5-aminolevulinic acid (5-ALA), or derivatives thereof, in this method, and a device suitable therefor.

IPC Classes  ?

• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
• G01N 21/64 - FluorescencePhosphorescence

Abstract

The invention relates to antibodies that recognize SARS-CoV-2 spike protein (SARS2-S). In some embodiments, the antibodies bind to SARS2-S with high affinity and potently neutralize a broad range of SARS-CoV-2 variants of concern. In some embodiments, the antibodies provide a means of preventing, treating or ameliorating SARS2 infection. In some embodiments, the antibodies are used in diagnostic assays (e.g. serodiagnostic assays for SARS2).

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 31/14 - Antivirals for RNA viruses
• C12N 15/13 - Immunoglobulins

Abstract

e.g.e.g. serodiagnostic assays for SARS2).

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 31/14 - Antivirals for RNA viruses
• C12N 15/13 - Immunoglobulins

Abstract

A fiber optic needle probe (100) comprising a length of optical fiber (10) inside a hollow needle (20) for supporting the optical fiber along its length. A distal end (10e) of the optical fiber (10) is formed by a formed convex tip (10t) protruding beyond a distal end (20e) of the hollow needle (20). Preferably, the distal end of the optical fiber (10) is formed by a formed conical tip with a cone angle less than hundred degrees. The shape of the convex tip (10t) formed at the distal end (10e) of the optical fiber (10) is found particularly suitable for repeated insertion into a tissue with minimal tendency of tissue residue sticking to the tip.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
• A61B 5/1459 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters invasive, e.g. introduced into the body by a catheter
• G02B 6/00 - Light guidesStructural details of arrangements comprising light guides and other optical elements, e.g. couplings

Abstract

The present invention provides a method for quantifying a monoclonal (M-) protein in a sample of a subject, the method comprising the steps of:—subjecting a serum sample of a subject to serum protein electrophoresis (SPE) in a gel, preferably serum protein electrophoresis in an agarose gel, to separate serum proteins into different serum protein fractions, optionally followed by immunofixation electrophoresis (IFE) and further optionally involving immunostaining of the gel;—excising from said gel a gel part comprising, or suspected of comprising, a M-protein;—performing an enzymatic digestion of proteins present in said gel part in order to provide a peptide digest comprising at least one M-protein peptide;—subjecting said peptide digest comprising said at least one M-protein peptide to liquid chromatography-mass spectrometry (LC-MS) to determine a quantity of said at least one M-protein peptide, thereby quantifying said M-protein in said sample.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention refers to a marker set for determining a PCL-like transcriptomic status in a sample which is indicative for a disease. Further, a method for determining a PCL-like transcriptomic status in a sample is provided by the present invention. In addition, the marker set and/or the method of the present invention is used for selecting an active agent for use in the treatment and/or prevention of a disease. In addition, the present invention refers to kits comprising means for determining the PCL-like transcriptomic status based on the marker set in a sample.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention refers to a marker set for determining a PCL-like transcriptomic status in a sample which is indicative for a disease. Further, a method for determining a PCL-like transcriptomic status in a sample is provided by the present invention. In addition, the marker set and/or the method of the present invention is used for selecting an active agent for use in the treatment and/or prevention of a disease. In addition, the present invention refers to kits comprising means for determining the PCL-like transcriptomic status based on the marker set in a sample.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

In an aspect of the invention there is provided an insufflator apparatus for exposing structures within a cavity of the human body for a diagnostic and/or therapeutic endoscopic procedure, comprising: an insufflation gas supply valve, adapted to provide insufflation gas to a pressure regulator; the pressure regulator, adapted to supply insufflation gas into the cavity of the human body via an input mechanism attachable to the human body, a means for determining a pressure level in the body cavity; an insufflator vent mechanism adapted to release excess insufflation gas volume returning from the pressure regulator; an insufflator controller arranged to real-time adapt an insufflation rate of said insufflation gas via said gas supply valve and vent mechanism at a set average pressure level in the body cavity in accordance with the means for determining the pressure level in the body cavity; and wherein the pressure regulator has a limited volume for temporarily storing a gas returning from the body cavity to thereby avoid transient pressure deviations from the set average pressure level in the body cavity, e.g. due to coughing or mechanical ventilation and s allowing the gas to return to the body cavity to maintain the set average pressure.

IPC Classes  ?

• A61M 13/00 - Insufflators for therapeutic or disinfectant purposes
• A61B 17/34 - TrocarsPuncturing needles

Abstract

The present invention provides a method for typing a tumor micro-environment (TME) of a solid tumor as being of the immune phenotype T cell-inflamed, T cell-excluded or T cell-ignored, comprising the steps of: - providing a test sample of a solid tumor comprising a TME from a subject; - measuring in said test sample the gene expression level for: (i) at least one gene selected from group 1 consisting of IGHG1, NKG7, IL2RG, IL7R, CCL18, PVRIG, PLAC8, CCL5, SIRPG, CORO1A, LCK, TRBC1, GZMB, CXCL13, and WARS; and (ii) at least one gene selected from group 2 consisting of COL5A1, SPON1, CAMK2N1, FAP, SPOCK1, COL1A1, SCGB2A1, AKR1C2, CPE, SCGB2A2, TCN1, TPSAB1, and MMP2; and (iii) at least one gene selected from group 3 consisting of PERP, THBS2, ASPN, COL10A1, TUFT1, GREM1, CEACAM6, ENTPD3, IGFBP5, PBX1, CXADR, GPRC5A, SDC1 and CALML5; - comparing the measured test sample gene expression levels to a reference gene expression level, and - typing the TME of said solid tumor of said subject as being T cell-inflamed, T cell-excluded or T cell-ignored on the basis of the comparison of said measured gene expression level and said reference gene expression level.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The invention is in the field of cell culturing. More specifically, it is in the field of generating and expanding myogenic cells from induced pluripotent stem (iPS) cells. The invention relates inter alia to cells generated and expanded via such a method, a growth medium specifically suited for the purpose of expanding isolated myogenic cells, and methods for screening compounds on cell structures such as myotubes and myofibers.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12N 5/074 - Adult stem cells
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms

Abstract

The present invention relates to a method to determine bisulfite conversion of unmethylated cytosine to uracil in genomic DNA, comprising the steps of providing a first set of amplification primers for amplifying bisulfite converted copies of a repetitive DNA element by qPCR and a second set of amplification primers for amplifying unconverted copies of said repetitive DNA element by qPCR, performing a multiplex qPCR with said first and second set of amplification primers to generate amplicons, and determining the bisulfite conversion efficiency by comparing the amounts of said first and second amplicon.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

In an implantable medical device, a method of communicating with a control device is provided. The method comprises receiving a first data message from the control device via a first physical communication channel, upon receiving the first message, activating a second physical communication channel different from the first physical communication channel and obtaining first authentication data of the control device, based on data provided in the first data message. The method further comprises receiving, via the second physical communication channel, a second message, verifying whether the second message originates from the control device, based on the obtained first authentication data and deactivating the second physical communication channel at the side of the implantable medical device if a result of the verifying is that the second message does not originate from the control device.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/372 - Arrangements in connection with the implantation of stimulators
• H04L 9/00 - Arrangements for secret or secure communicationsNetwork security protocols

Abstract

According to one aspect, an interstitial hyperthermia device has an electrode structure to be coupled to an electric power source for providing an alternating electric field for heating up a patients tissue. The device is provided with a hollow source guide for conducting a radiation source capsule to be moved by a guidewire. The hollow source guide has an inner wall for guiding the source capsule and an outer wall to be contacted with the patients tissue. The outer wall is provided with the electrode structure arranged on a circumference of the outer wall of the hollow source guide and having a dielectric layer shielding the electrode structure from the patients tissue.

IPC Classes  ?

• A61N 1/40 - Applying electric fields by inductive or capacitive coupling
• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy

Abstract

Methods are provided for treating an individual with cytotoxic T lymphocyte exhaustion by administering an effective dose of an annexin V agent. In some embodiments, the individual undergoing treatment is infected with HIV. The individual may be treated with highly active antiretroviral therapy (HAART).

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to a method for typing a subject for the presence or absence of a secondary liver cancer, comprising the steps of—measuring in a sample comprising peptides from a subject a peptide level for (i) a peptide comprising the amino acid sequence of SEQ ID NO:4 or a peptide comprising an amino acid sequence that has at least 90% sequence identity to the amino acid sequence of SEQ ID NO:4; and/or (ii) a peptide comprising the amino acid sequence of SEQ ID NO:1 or a peptide comprising an amino acid sequence that has at least 90% sequence identity to the amino acid sequence of SEQ ID NO:1; and—typing said subject for the presence or absence of said secondary liver cancer on the basis of the measured peptide level.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention relates to antibodies and antigen-binding fragments thereof that recognize coronavirus spike proteins(CoV-S), such asthe spike protein of Middle East respiratory syndrome coronavirusspike protein(MERS-S). In some embodiments, the antibodiesbind to CoV-Swith high affinity, inhibit CoV infection of human cells, inhibit CoV sialic acid-binding activity and/or bind to multiple types of CoV-S. In some embodiments, the antibodies provide a means of preventing, treating or ameliorating CoV infection.

IPC Classes  ?

• C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses
• A61P 31/14 - Antivirals for RNA viruses
• A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient

Abstract

The invention provides inter alia an engineered T cell, wherein said T cell is engineered to express a T cell receptor (TCR) or an antibody-based receptor that binds to a T cell epitope of human ropporin-1A (ROPN1) or human ropporin-1B (ROPN1B); wherein said T cell epitope is selected from the group consisting of SEQ ID NO:4, SEQ ID NO:43, SEQ ID NO:23, SEQ ID NO:56 and SEQ ID NO:24.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 4/12 - Peptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof from animalsPeptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof from humans
• C07K 14/725 - T-cell receptors

Abstract

The invention provides inter alia an engineered T cell, wherein said T cell is engineered to express a T cell receptor (TCR) or an antibody-based receptor that binds to a T cell epitope of human ropporin-1A (ROPN1) or human ropporin-1B (ROPN1B); wherein said T cell epitope is selected from the group consisting of SEQ ID NO:4, SEQ ID NO:43, SEQ ID NO:23, SEQ ID NO:56 and SEQ ID NO:24.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 4/12 - Peptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof from animalsPeptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof from humans
• C07K 14/725 - T-cell receptors
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present disclosure pertains to the field of personalized medicine and methods for treating bladder cancer. In some embodiments, the disclosure relates to the use of long non-coding RNA (lncRNA) and genomic signatures for the prognosis of individuals with bladder cancer. The present disclosure provides methods for subtyping bladder cancer. The present disclosure also provides methods and compositions for treating bladder cancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention relates to a method of diagnosing cancer in a subject comprising detecting in the DNA of said subject at least one hypermethylated CpG island associated with said cancer, wherein an elevation in the level of methylation in said CpG island of said subject, relative to the level of methylation in said CpG island of a control subject, is indicative of said CpG island being hypermethylated.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The invention provides a method for producing an auristatin-loaded liposome, comprising the steps of: - providing a liposome that encapsulates a remote loading agent; - generating a concentration gradient of said remote loading agent across the membrane of said liposome; - mixing said liposome with an aqueous medium comprising an auristatin; - loading said auristatin into said liposome; wherein said loading is driven by said concentration gradient; and - optionally, purifying an auristatin-loaded liposome.

IPC Classes  ?

• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Abstract

The invention relates to antibody conjugates comprising an antibody and a nanoparticle conjugated to the antibody, wherein the nanoparticle comprises a payload, such as a gene editing payload. In some embodiments, the antibody-conjugated nanoparticles provide a means for treating a disease. In some embodiments, the antibody-conjugated nanoparticles are used to correct genetic defects in specific cell populations.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The invention relates to antibody conjugates comprising an antibody and a nanoparticle conjugated to the antibody, wherein the nanoparticle comprises a payload, such as a gene editing payload. In some embodiments, the antibody-conjugated nanoparticles provide a means for treating a disease. In some embodiments, the antibody-conjugated nanoparticles are used to correct genetic defects in specific cell populations.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• A61P 35/00 - Antineoplastic agents

Abstract

Described herein is a composition and method of preventing COVID-19 with lipid-peptide fusion antiviral therapy.

IPC Classes  ?

• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61P 31/14 - Antivirals for RNA viruses
• C07K 14/08 - RNA viruses

Abstract

Described herein is a composition and method of preventing COVED- 19 with lipid-peptide fusion antiviral therapy.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61P 31/14 - Antivirals for RNA viruses
• C07K 14/08 - RNA viruses
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids

Abstract

During hyperthermia treatment of the head and neck area a conventional water bolus, used in such treatment for guiding electromagnetic waves and cooling the patient's skin, may collapse onto the patients face due to the weight and/or pressure of the water inside the water bolus. An insert may be provided inside the water bolus to remedy this, wherein the insert provides additional stiffness and thus resistance against the water's weight and pressure. The insert however should not be too resistant against the shape of the patient, and thus an insert is provided with a first stiffness in a first load direction and a second stiffness in a second load direction, wherein the first stiffness is not equal to the second stiffness.

IPC Classes  ?

• A61F 7/00 - Heating or cooling appliances for medical or therapeutic treatment of the human body

Abstract

According to one method, a sample with cells contains a phototagging agent. The sample is imaged to identify at least one target cell to be isolated. The identified target cell in the sample is selectively irradiated with photo-activating light for selectively activating the phototagging agent in the target cell to change its fluorescence response. The irradiated target cell is isolated from other cells in the sample based on a difference in its fluorescence response compared to non-activated phototagging agent in the other cells. Further aspects are directed to a corresponding microscope system and chemical compound for use as the phototagging agent.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12M 1/00 - Apparatus for enzymology or microbiology
• C09B 11/24 - Phthaleins containing amino groups
• G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
• G01N 21/64 - FluorescencePhosphorescence
• G02B 21/00 - Microscopes

Abstract

The invention relates to a recombinant adenovirus nucleic acid wherein the gene encoding protein V and/or the gene encoding protein VII is placed under control of a heterologous promoter, to a recombinant adenovirus nucleic acid wherein the adenoviral nucleotide sequence is mutated in such a way that it is no longer capable of producing one or more of the coat proteins, to cellular vesicles filled with such adenoviral material, cells provided with such adenoviral material and to methods and use thereof.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 15/86 - Viral vectors
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
• A61K 35/761 - Adenovirus

Abstract

An insufflator for exposing structures within an internal cavity forming a confined volume within an animal or human body, the apparatus including: an input conduit for exchanging gas with the confined volume; a gas insufflator for insufflation of gas into the confined volume through the input conduit, wherein the gas insufflator is configured to deliver an insufflator pressure to the confined volume, wherein the gas insufflator is configured to (super)impose at least one pressure or flow oscillation to obtain a forced oscillating pressure or flow delivered to the confined volume, the forced oscillating pressure or flow having at least one component with a frequency and an amplitude; a monitoring unit for monitoring a response of the internal cavity to the forced oscillating pressure or flow for determining one or more physical properties of the internal cavity; and an adapter unit for adjusting the insufflation pressure based on the determined one or more physical properties of the internal cavity.

IPC Classes  ?

• A61M 13/00 - Insufflators for therapeutic or disinfectant purposes

Abstract

The current invention pertains an inhibitor of an S100 protein, preferably an inhibitor of an S100A8 or S100A9 protein, for the prevention or treatment of a myeloproliferative neoplasm. In particular, the invention pertains to an inhibitor of an S100A8 orS100A9 protein, for the prevention ortreatment of primary myelofibrosis. The invention further pertains to an diagnostic method for identifying a subject suffering from a myeloproliferative neoplasm, comprising a step of detecting the presence of an S100 protein, preferably S100A8 or S100A9, in a biological sample.

IPC Classes  ?

• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril
• A61P 35/00 - Antineoplastic agents
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons

Abstract

A method for distinguishing cells in a sample (S). The sample is provided with photoaffinity tags (T). Each tag (T) comprises a photoreactive moiety (Th) configured to hind to a nearby cell upon irradiation by photoactivating light (La), and a molecular identification structure (Ti) connected to the photoreactive moiety, A target location (St) of the sample (S) is determined with a target cell (Ct) to be distinguished. The target location (St) is selectively irradiated with the photoactivating light (La) to cause a photoactivated tag (T) to bind with the target cell (Ct) in the target location (St). The target cell (Ct) is distinguished from other cells (C) in the sample (S) by identifying the molecular identification structure (Ti) of the tag (T") bound to the target cell (Ct).

IPC Classes  ?

• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• C09B 11/08 - Phthaleins
• C12M 1/00 - Apparatus for enzymology or microbiology
• G01N 15/14 - Optical investigation techniques, e.g. flow cytometry

Abstract

The current invention pertains an inhibitor of an S100 protein, preferably an inhibitor of an S100A8 or S100A9 protein, for the prevention or treatment of a myeloproliferative neoplasm. In particular, the invention pertains to an inhibitor of an S100A8 orS100A9 protein, for the prevention ortreatment of primary myelofibrosis. The invention further pertains to an diagnostic method for identifying a subject suffering from a myeloproliferative neoplasm, comprising a step of detecting the presence of an S100 protein, preferably S100A8 or S100A9, in a biological sample.

IPC Classes  ?

• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril
• A61P 35/00 - Antineoplastic agents
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons

Abstract

The invention relates to a device (1, 1') and a method for obtaining an indicator of microcirculatory condition of a patient. The device (1, 1') comprises at least one first sensor (13) for measuring data indicative of first carbon dioxide levels, in particular tissue carbon dioxide levels, at least one second sensor (12) for measuring data indicative of second carbon dioxide levels, in particular transcutaneously measured arterial blood carbon dioxide levels, and a control unit (4) for determining a measure of microcirculation, in particular changes in tissue perfusion, preferably in septic patients, on the basis of the tissue carbon dioxide level and the transcutaneously measured arterial blood carbon dioxide level.

IPC Classes  ?

• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/1477 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means non-invasive
• A61B 5/1491 - Heated applicators

Abstract

The invention relates to a device (1, 1') and a method for obtaining an indicator of microcirculatory condition of a patient. The device (1, 1') comprises at least one first sensor (13) for measuring data indicative of first carbon dioxide levels, in particular tissue carbon dioxide levels, at least one second sensor (12) for measuring data indicative of second carbon dioxide levels, in particular transcutaneously measured arterial blood carbon dioxide levels, and a control unit (4) for determining a measure of microcirculation, in particular changes in tissue perfusion, preferably in septic patients, on the basis of the tissue carbon dioxide level and the transcutaneously measured arterial blood carbon dioxide level.

IPC Classes  ?

• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
• A61B 5/1477 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means non-invasive
• A61B 5/1491 - Heated applicators
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The invention relates to a device (1) and a method for obtaining an indicator of the microcirculatory condition of a patient. The device (1) comprises at least one sensor (2) for measuring data indicative of an arterial blood oxygen level, at least one sensor (3) for measuring data indicative of a tissue oxygen level and a control unit (4) for determining a measure of microcirculation, in particular changes in tissue perfusion on the basis of the tissue oxygen level and the arterial blood oxygen level.

IPC Classes  ?

• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
• A61B 5/1486 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
• A61B 5/1491 - Heated applicators

Abstract

The invention relates to a device (1) and a method for obtaining an indicator of the microcirculatory condition of a patient. The device (1) comprises at least one sensor (2) for measuring data indicative of an arterial blood oxygen level, at least one sensor (3) for measuring data indicative of a tissue oxygen level and a control unit (4) for determining a measure of microcirculation, in particular changes in tissue perfusion on the basis of the tissue oxygen level and the arterial blood oxygen level.

IPC Classes  ?

• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
• A61B 5/1486 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
• A61B 5/1491 - Heated applicators
• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

A method of manufacturing a microstructure comprises printing a positive mold structure, filling the positive mold structure with a second material to form an elastically deformable negative mold structure, filling the negative mold structure with a third material to form the microstructure, and releasing the microstructure from the negative mold structure. Advantageously, the negative mold structure can be stretched to facilitate the release of the microstructure. For example, the microstructure comprises a chamber with capped micropillars for the generation and/or analysis of muscle tissue.

IPC Classes  ?

• B29C 39/00 - Shaping by casting, i.e. introducing the moulding material into a mould or between confining surfaces without significant moulding pressureApparatus therefor
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12M 1/32 - Inoculator or sampler multiple field or continuous type
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12M 1/26 - Inoculator or sampler

Abstract

The disclosure relates to methods and devices for monitoring the concentration of a substance, preferably oxygen, in a cell or tissue, e.g., in cells of the human skin. In particular, it provides a method for determining the concentration of a quencher, such as oxygen and/or the concentration of a probe, e.g., a heme precursor such as protoporphyrin IX (PplX), wherein the probe is capable of exhibiting luminescence (delayed fluorescence (DF) or phosphorescence) and or transient triplet absorption, preferably, deDF, in a living cell. The method comprises steps of exciting the probe, measuring the lifetime of the luminescence exhibited by said probe, wherein, in the presence of the quencher, the lifetime is shortened as compared to the lifetime in the absence of the quencher, and correlating said lifetime with said concentration. The disclosed method leads to more precise results than conventional methods, because of adaptations based on the understanding of the influence of the concentration of the probe and its excitation fluence rate (intensity) on the analysis. For example, the simultaneous time-resolved detection of the probe excimer and monomer DF allows estimation of the probe concentration and compensation of the probe self-quenching effect in the quencher concentration calculation, increasing the measurement precision. Taking into account second order triplet interactions also permits the interpretation of non-exponential decays and further improvement of the quencher and probe concentration estimation. Disclosed methods rely, e.g., on measurement at different emission wavelengths and application of an adaptive Stern-Volmer relationship, the decay central fitting method and/or a mixed orders approach. Said method can be applied, e.g., for bedside monitoring of patients. Also disclosed is the use of the PplX precursor 5-aminolevulinic acid (5-ALA), or derivatives thereof, in this method, and a device suitable therefor.

IPC Classes  ?

• G01N 21/64 - FluorescencePhosphorescence
• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

An MR excitation sequence comprises a repeated block (A) of excitation pulses. Each block (A) comprises a set of interleaved RE pulses with alternating small and large flip angle (α,γ) applied along different axes (x,y) to form a balanced sequence such as αχ,γγ,αγ,γχ. The sequence is simultaneously sensitive to various parameters such as PD, Tl, T2, B1 and BO keeping a high coherence and avoiding the formation of banding artifacts.

IPC Classes  ?

• G01R 33/44 - Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
• G01R 33/50 - NMR imaging systems based on the determination of relaxation times

Abstract

The present invention is direct to the treatment of Pompe disease by administration of an enzyme or nucleic acid encoding for said enzyme suitable for Enzyme Replacement Therapy for Pompe disease in combination with the administration of an antisense oligomeric compound that modulates the splicing of acid alpha-glucosidase (GAA) gene.

IPC Classes  ?

• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 3/00 - Drugs for disorders of the metabolism
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline

Abstract

The present invention provides inter alia a self-assembling nanoparticle that displays on the outer surface a receptor binding domain (RBD) of a coronavirus spike (S) protein. The present prevention also relates to vaccine formulations and methods for therapeutic and prophylactic interventions for coronaviral infection, more in particular SARS-CoV-2, the causal agent of COVID-19.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses

Abstract

This disclosure provides methods of using BAF complex modulating compounds as inhibitors of BAF-mediated transcription in target cells. The BAF complex modulating compounds include 12-membered macrolactam compounds that can target a BAF-specific subunit (e.g., ARID1A) to prevent nucleosomal positioning, relieving transcriptional repression of HIV-1. The subject methods can provide for reversal of latency of HIV-1 in cells in vitro or in vivo. Use of the macrolactam BAF complex modulating compounds represent a method of HIV latency reversal with a unique mechanism of action, which can be optionally combined with other Latency Reversal Agents to improve reservoir targeting. The subject methods can be utilized in conjunction with any convenient methods of treating HIV or HIV latency, including methods related to immune system activation, antiretroviral therapies and/or anti-HIV agents.

IPC Classes  ?

• A61K 31/4427 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems
• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61P 31/18 - Antivirals for RNA viruses for HIV

Abstract

A method for magnetic resonance imaging (MRI) comprises applying a consecutive series of MRI sequences to a target volume (V) according to experimental settings (TR, α, β). A discrete sequence of transient response signals (Sn, Sn+1, Sn+2) is measured and fitted to a fit function (F) that is continuously dependent on a sequence number (n) of the respective MRI sequence (Pn) and corresponding response signal (Sn). A shape of the fit function is determined according to an analytically modelled evolution by the experimental parameters (TR, α, β) as well as variable intrinsic parameters (r, λ3, φ, δ) to be fitted. For example, the model is based on an equivalent harmonic oscillator. The intrinsic parameters of the fit function can be related to the intrinsic properties (PD, T1, T2) of the spin systems and used for imaging the target volume (V). Various optimizations of contrast can be achieved by tuning the experimental settings according to the model.

IPC Classes  ?

• G01R 33/50 - NMR imaging systems based on the determination of relaxation times
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• G01R 33/54 - Signal processing systems, e.g. using pulse sequences
• G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
• G01R 33/561 - Image enhancement or correction, e.g. subtraction or averaging techniques by reduction of the scanning time, i.e. fast acquiring systems, e.g. using echo-planar pulse sequences

Goods & Services

Provision of training and education, conducting of courses; organization of congresses, seminars, information meetings (educational) and other educational events; organization of events for cultural, entertainment and sporting purposes in the context of charitable activities; publication of printed matter and other publications. Science and technology services as well as associated research- and design services; industrial analysis and research services; computer and software design and development; medical research services.

Abstract

The present invention provides a reporter system comprising (i) a gene expression construct for expression in a cell of a reporter gene, said reporter gene encoding a fusion protein comprising a transmembrane domain fused in-frame to a reporter domain, wherein said transmembrane domain upon insertion of the fusion protein into the cell membrane anchors the fusion protein in the cell membrane while expressing the reporter domain at the cell surface, and (ii) a reporter peptide labeled with a radiolabel, wherein said reporter domain comprises the large polypeptide subunit of a split luciferase, and wherein said reporter peptide comprises the small peptide subunit of said split luciferase, wherein both subunits associate by complementation to assemble into a luciferase complex.

IPC Classes  ?

• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12Q 1/66 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving luciferase
• A61B 6/03 - Computed tomography [CT]
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61K 51/00 - Preparations containing radioactive substances for use in therapy or testing in vivo

Abstract

The invention relates to antibodies and antigen-binding fragments thereof that recognize SARS-Cov-2 spike proteins (SARS2-S). In some embodiments, the antibodies bind to SARS2-S with high affinity and/or inhibit SARS-Cov-2 infection of human cells. In some embodiments, the antibodies provide a means of preventing, treating or ameliorating SARS2 infection. In some embodiments, the antibodies are used in diagnostic assays (e.g. serodiagnostic assays for SARS2).

IPC Classes  ?

• A61P 31/14 - Antivirals for RNA viruses
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses

Abstract

A device for protecting a gastro-intestinal anastomosis, in particular a colorectal anastomosis or an esophageal anastomosis, is provided. The device comprises a support structure providing a passage for allowing passage of gastro-intestinal content such as faecal matter and/saliva from a first end to a second end of the support structure, a first expandable compartment, connected to the support structure and circumferentially surrounding the support structure at or near the first end, wherein an outer diameter of the first expandable compartment is larger than an outer diameter of the support structure the first expandable compartment is in an expanded state.

IPC Classes  ?

• A61B 17/00 - Surgical instruments, devices or methods
• A61B 17/11 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for performing anastomosisButtons for anastomosis
• A61F 2/04 - Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
• A61F 2/848 - Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents having means for fixation to the vessel wall, e.g. barbs

Abstract

The invention relates to the field of flow cytometry and more particularly to a panel of antibody reagents conjugated to fluorescent compounds. Provided are reagent compositions, comprising at least eight distinct fluorochrome-conjugated antibodies comprising a set of at least there identification antibodies for the identification of a leukocyte population of interest and at least four characterization antibodies for further characterization and/or classification of said leukocyte population. Also provided are kits and methods related to the reagent compositions.

IPC Classes  ?

• G01N 33/533 - Production of labelled immunochemicals with fluorescent label
• G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
• G01N 33/49 - Physical analysis of biological material of liquid biological material blood
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/532 - Production of labelled immunochemicals
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 15/1404 - Handling flow, e.g. hydrodynamic focusing

Abstract

The invention relates to a group of Y-chromosomal short tandem repeat (Y-STR) markers comprising at least one rapidly mutating (RM) Y-STR marker selected from the group consisting of DYF1000, DYF1001, DYF1002, DYR88, DYS685, DYS688, DYS712, DYS1003, DYS1007, DYS1010 and DYS1012. The invention further relates to a set of amplification primers comprising primers for the amplification of at least one Y-STR marker according to the invention, to methods for amplifying an allele of at least one Y-STR marker, to a kit for identifying an allele of a Y-STR marker by amplification and electrophoretic detection or sequencing detection, and by sequencing of non-amplified DNA, and to the use of the group of Y-STR markers for typing male individuals.

IPC Classes  ?

• C12Q 1/6858 - Allele-specific amplification

Abstract

A surgical navigation system (100) comprises a first detection system (10) configured to detect a first marker (11). A headset (40) comprises goggles (30) and a second detection system (20) configured to detect a distinct, reference marker (21). The goggles (30) provide a display to show an augmented image (la) in a user's field of view (Vu). A controller (50) is configured to generate the augmented image (la) based at least on respective coordinates (P11,P21) of the markers (11,21), and a predetermined spatial relation (ΔΡ) between the coordinates (P11,P21).

IPC Classes  ?

• A61B 34/20 - Surgical navigation systemsDevices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
• G02B 27/01 - Head-up displays
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
• A61B 90/50 - Supports for surgical instruments, e.g. articulated arms

Abstract

−5. Also provided are diagnostic kits and methods for detecting MRD.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 39/02 - Bacterial antigens
• A61K 39/09 - Streptococcus

Abstract

The present invention provides a method for quantifying a monoclonal (M-) protein in a sample of a subject, the method comprising the steps of: - subjecting a serum sample of a subject to serum protein electrophoresis (SPE) in a gel, preferably serum protein electrophoresis in an agarose gel, to separate serum proteins into different serum protein fractions, optionally followed by immunofixation electrophoresis (IFE) and further optionally involving immunostaining of the gel; - excising from said gel a gel part comprising, or suspected of comprising, a M-protein; - performing an enzymatic digestion of proteins present in said gel part in order to provide a peptide digest comprising at least one M-protein peptide; - subjecting said peptide digest comprising said at least one M-protein peptide to liquid chromatography-mass spectrometry (LC-MS) to determine a quantity of said at least one M-protein peptide, thereby quantifying said M-protein in said sample.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 27/447 - Systems using electrophoresis

Abstract

The invention provides novel immunogenic peptides derived from the X protein and polymerase protein of hepatitis B virus (HBV). The peptides contain epitopes that are well-conserved across multiple HBV variants and are derived from regions of proteins that are essential for viral replication. Moreover, the novel HBV antigens bind multiple HLA types and epitopes that elicit IFN? responses in PBMCs from HBV resolvers have been identified.

IPC Classes  ?

• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61K 38/10 - Peptides having 12 to 20 amino acids
• C07K 14/02 - Hepadnaviridae, e.g. hepatitis B virus

Abstract

γγ responses in PBMCs from HBV resolvers have been identified.

IPC Classes  ?

• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61K 38/10 - Peptides having 12 to 20 amino acids
• C07K 14/02 - Hepadnaviridae, e.g. hepatitis B virus

Abstract

In an aspect of the invention there is provided an insufflator apparatus for exposing structures within a cavity of the human body for a diagnostic and/or therapeutic endoscopic procedure, comprising: an insufflation gas supply valve, adapted to provide insufflation gas to a pressure regulator; the pressure regulator, adapted to supply insufflation gas into the cavity of the human body via an input mechanism attachable to the human body, a means for determining a pressure level in the body cavity; an insufflator vent mechanism adapted to release excess insufflation gas volume returning from the pressure regulator; an insufflator controller arranged to real-time adapt an insufflation rate of said insufflation gas via said gas supply valve and vent mechanism at a set average pressure level in the body cavity in accordance with the means tor determining the pressure level in the body cavity; and wherein the pressure regulator has a limited volume for temporarily storing a gas returning from the body cavity to thereby avoid transient pressure deviations from the set average pressure level in the body cavity, e,g. due to coughing or mechanical ventilation and allowing the gas to return to the body cavity to maintain the set average pressure.

IPC Classes  ?

• A61M 13/00 - Insufflators for therapeutic or disinfectant purposes
• A61B 17/34 - TrocarsPuncturing needles

Abstract

The present invention is directed to antisense oligomeric compounds that may be used in the treatment Pompe disease as well as method for modulating the splicing of the GAA gene and method to treat Pompe disease. Also pharmaceutical compositions comprising the antisense oligomeric compounds are part of the invention.

IPC Classes  ?

• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

The present invention relates to a method to determine bisulfite conversion of unmethylated cytosine to uracil in genomic DNA, comprising the steps of providing a first set of amplification primers for amplifying bisulfite converted copies of a repetitive DNA element by qPCR and a second set of amplification primers for amplifying unconverted copies of said repetitive DNA element by qPCR, performing a multiplex qPCR with said first and second set of amplification primers to generate amplicons, and determining the bisulfite conversion efficiency by comparing the amounts of said first and second amplicon.

IPC Classes  ?

• C12Q 1/6858 - Allele-specific amplification

Abstract

This invention relates to the field of primary immunodeficiencies (PID), more specifically to means and method for the diagnosis of PID of the lymphoid system. Provided are unique reagent compositions for the flow cytometric immunophenotyping of leukocytes comprising fluorochrome-conjugated antibodies directed against various specific combinations of markers. Also provided are kits comprising the reagent compositions, and methods using the same.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
• G01N 33/49 - Physical analysis of biological material of liquid biological material blood
• G01N 15/01 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
• G01N 15/10 - Investigating individual particles

Abstract

The invention relates to a method for typing a subject for the presence or absence of a secondary liver cancer, comprising the steps of - measuring in a sample comprising peptides from a subject a peptide level for (i) a peptide comprising the amino acid sequence of SEQ ID NO:4 or a peptide comprising an amino acid sequence that has at least 90% sequence identity to the amino acid sequence of SEQ ID NO:4; and/or (ii) a peptide comprising the amino acid sequence of SEQ ID NO:1 or a peptide comprising an amino acid sequence that has at least 90% sequence identity to the amino acid sequence of SEQ ID NO:1; and - typing said subject for the presence or absence of said secondary liver cancer on the basis of the measured peptide level.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

A microfluidic device for holding three dimensional cell structures (2), with a top cover plate (3), a bottom cover plate (4), and an insert (5) having a membrane (6) provided in an aperture in the insert (5) and extending in a plane of the insert (5). In operation the insert (5) is positioned between the top cover plate (3) and bottom cover plate (4) to form two flow channels (3a; 4a) on either side of the insert (5). The membrane (6) is provided with a plurality of pores (6a) for holding three dimensional cell structures, with a pore size of at least 50pm. The microfluidic device (1) may be applied for a real-time imaging application.

IPC Classes  ?

• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• C12M 1/00 - Apparatus for enzymology or microbiology
• G01N 21/77 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means

Abstract

The invention relates to methods for rapid in vitro-generation of viable, exhausted T cells, comprising culturing of T cells in a medium comprising at least IL-7 and/or IL-15, and repeated antigen stimulation of said T cells to rapidly generate exhausted T cells. The invention further relates to a method for treating said T cells to prevent, alleviate, or accelerate the generation of exhausted T cells. Further, this invention relates to a cell culture comprising viable, exhausted T cells.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Goods & Services

Scientific services relating to the identification, selection and isolation of human tissues and cells; Scientific research; Technical research by means of microscopy systems; Design of optical and microoptical components; Optical research; laboratory services; Design and development of software for the acquisition and control of microscopy systems for research and medical imaging; technical adjustment of microscopy systems for research and medical imaging; Development of pharmaceutical preparations and medicines; Research in relation to medicines; Pharmaceutical research services. Medical services by means of identifying, selecting, isolating, removing and treating cells; Medical imaging.